{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-021988","form_type":"8-K","ticker":"RCUS","cik":"0001724521","company_name":"Arcus Biosciences, Inc.","filed_at":"2023-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.241989+00:00","generated_at":"2026-06-15T01:19:24.460182+00:00","sec_items":["1.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Arcus gets $35M upfront from Gilead to collaborate on up to 4 inflammatory disease targets","bullets":["Upfront payment of $35M from Gilead Sciences under Amendment No. 2 to existing collaboration.","Arcus will conduct research on up to 4 jointly selected targets for inflammatory diseases.","If Gilead exercises early option on first 2 programs, Arcus eligible for up to $420M in option/milestone payments plus tiered royalties per program.","For other option exercises, parties co-develop/co-commercialize in US with cost and profit sharing.","Gilead has two prespecified time points to exercise options for each program."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-021988","json":"https://secwatch.observer/filing/0000950170-23-021988.json","markdown":"https://secwatch.observer/filing/0000950170-23-021988.md","text":"https://secwatch.observer/filing/0000950170-23-021988.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1724521/000095017023021988/0000950170-23-021988-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1724521/000095017023021988/rcus-20230515.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T01:19:24.460182+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6857c591c780d2d37105ba708877f826f564b480","claim":"Arcus Biosciences, Inc. amended Option, License and Collaboration Agreement Amendment No. 2 with Gilead Sciences, Inc. valued at Upfront payment of $35 million; potential option and milestone payments up to $420 million per progr (effective 2023-05-15).","evidence_excerpt":"On May 15, 2023, Arcus Biosciences, Inc. (“Arcus”) entered into an amendment (“Amendment No. 2”) to its Option, License and Collaboration Agreement with Gilead Sciences, Inc. (“Gilead”) dated May 27, 2020.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1724521/000095017023021988/0000950170-23-021988-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"collaboration"},{"label":"Counterparty","value":"Gilead Sciences, Inc."},{"label":"Value","value":"Upfront payment of $35 million; potential option and milestone payments up to $420 million per progr"},{"label":"Effective","value":"2023-05-15"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}